| Dr Jeffery James Eapen, MD | |
|
12222 Merit Dr Ste 600, Dallas, TX 75251-3294 | |
| (972) 715-5000 | |
| (972) 715-9976 |
| Full Name | Dr Jeffery James Eapen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 12222 Merit Dr Ste 600, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124513700 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 125073345 (Illinois) | Secondary |
| 207L00000X | Anesthesiology | U4792 (Texas) | Primary |
| Entity Name | U S Anesthesia Partners Of Texas, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208564 PECOS PAC ID: 7315850351 Enrollment ID: O20031106000563 |
News Archive
BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.
Inc. magazine ranked Signature Genomic Laboratories no. 1012 on its third annual Inc. 5000, an exclusive ranking of the nation's fastest-growing private companies. The company, which performs microarray-based diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, experienced three-year sales growth of 302.9%, more than twice that of the Inc. 5000 industry median and over 12 times the industry benchmark. Signature was also ranked 70th of companies in the healthcare sector.
Autism spectrum disorders (ASD) are not completely understood neurodevelopmental disorders diagnosed solely on the basis of behavioral assessments of social, communicative and repetitive symptoms. T
GTC Biotherapeutics, Inc.'s total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share, for the first nine months of 2008.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffery James Eapen, MD Po Box 840853, Dallas, TX 75284-3714 Ph: (972) 233-1999 | Dr Jeffery James Eapen, MD 12222 Merit Dr Ste 600, Dallas, TX 75251-3294 Ph: (972) 715-5000 |
News Archive
BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.
Inc. magazine ranked Signature Genomic Laboratories no. 1012 on its third annual Inc. 5000, an exclusive ranking of the nation's fastest-growing private companies. The company, which performs microarray-based diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, experienced three-year sales growth of 302.9%, more than twice that of the Inc. 5000 industry median and over 12 times the industry benchmark. Signature was also ranked 70th of companies in the healthcare sector.
Autism spectrum disorders (ASD) are not completely understood neurodevelopmental disorders diagnosed solely on the basis of behavioral assessments of social, communicative and repetitive symptoms. T
GTC Biotherapeutics, Inc.'s total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share, for the first nine months of 2008.
› Verified 8 days ago
Lee M. Lunsford, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-8000 | |
Dr. Stephanie C Jones, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-9374 | |
Dr. Alfredo Ruben Lopez, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6606 Lbj Fwy Ste 200, Dallas, TX 75240 Phone: 972-715-5000 Fax: 972-715-9976 | |
Dr. Elvis Tsang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 12222 Merit Dr Ste 600, Dallas, TX 75251 Phone: 972-715-5000 Fax: 972-715-9976 | |
Dr. Christopher D Lecheminant, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6606 Lbj Fwy Ste 200, Dallas, TX 75240 Phone: 972-715-5000 | |
Dr. Mihir N Rane, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3625 N Hall St Ste 800, Dallas, TX 75219 Phone: 214-252-3500 | |
Lisa Gu, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-6400 |